TABLE 5.
Reported proportion of patients experiencing clinically significant improvements in anxiety and sleep quality after receiving treatment with cannabis‐based medicinal products (CBMPs).
| PROM | Follow‐up interval | Oils | Dried flower | Oils and dried flower | p‐Value |
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | |||
| GAD‐7 | 1 month | 142 (22.15) | 94 (40.00) | 169 (33.67) | <0.001*** |
| GAD‐7 | 3 months | 143 (22.31) | 92 (39.15) | 178 (35.46) | <0.001*** |
| GAD‐7 | 6 months | 143 (22.31) | 90 (38.30) | 181 (36.06) | <0.001*** |
| GAD‐7 | 12 months | 138 (21.53) | 93 (39.57) | 175 (34.86) | <0.001*** |
| SQS | 1 month | 144 (22.46) | 75 (31.91) | 161 (32.07) | <0.001*** |
| SQS | 3 months | 153 (23.87) | 76 (32.34) | 170 (33.86) | <0.001*** |
| SQS | 6 months | 155 (24.18) | 84 (35.74) | 180 (35.86) | <0.001*** |
| SQS | 12 months | 154 (24.02) | 80 (34.04) | 176 (35.06) | <0.001*** |
Note: Clinically significant improvements in GAD‐7 and SQS were assessed at regular intervals, and the data were analyzed using the chi‐squared test.
Abbreviations: GAD‐7, generalized anxiety disorder‐7; n, number of patients; PROM, patient‐reported outcome measures; SQS, Single‐Item Sleep Quality Scale.
*
p < 0.050;
**
p < 0.010;
***
p < 0.001.